Financial Statements

Financial Year - 2021-22 < AY - 22-23 >

Contents

I	Notice	to.	AGM

- II Director's Report
- III MGT-7 Share Holder's List
- IV Independent Auditors Report
- V Audited Financial Statement BS, P&L & Schedules
- VI Notes to Accounts
- VII Computation of Total Income
- VIII IT Return Acknowledgement
- IX AOC-4 and MGT-7

CONFIDE PHARMACEUTICALS PRIVATE LIMITED

PAN: AAGCC9723P, GSTIN: 29AAGCC9723P2ZU

No. 196, 1st Floor Raghavendra Layout, Chikabanavara Bangalore Bangalore KA 560090

CIN: U74999KA2017PTC1025

BALANCE SHEET AS		₹ in Thousands			
Particualrs	Note No.	As at	As at		
		March 31, 2022	March 31, 2021		
I. EQUITY AND LIABILITIES					
Equity					
(a) Equity Share Capital	1	100.00	100.0		
(b) Other Equity		164.40	(50		
(i) Reserves and surplus	2	164.40	-650.		
2 Liabilities					
(I) Non-Current Liabilities					
(a) Financial liabilities	=	-			
(i) Borrowings	-	1,025.07			
(ii) Lease liabilities	-	-			
(b) Provisions					
(c) Other non-current liabilities	-	1.03	1		
(II) Current liabilities					
(a) Financial liabilities					
(i) Borrowings	3	-			
(ii) Lease liabilities					
(iii) Trade Payables		-	1,042		
(a) total outstanding dues of micro enterprises and small enterprises	s	-			
(b) total outstanding dues of Creditors other than micro enterprises	and small enterprises	-			
(b) Other current liabilities	4	-			
(c) Provisions	5	878.80	525		
(d) Income tax liabilities(Net)	-				
(d) Income tax liabilities(Net) TOTAL	-	2,169.30	1,018.		
	-	2,169.30	1,018		
TOTAL I. ASSETS Non-current assets	-				
TOTAL ASSETS Non-current assets (i) Tangible Assets	-	2,169.30 58.90			
TOTAL . ASSETS Non-current assets (i) Tangible Assets (ii) Intangible assets	-	58.90			
I. ASSETS Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress	-	58.90 - -			
I. ASSETS Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development		58.90 - - -	41		
I. ASSETS Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets	-	58.90 - -	41		
I. ASSETS Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments		58.90 - - -	41		
Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others		58.90 - - - -	41		
Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others (vi) Long term loans and advances		58.90 - - -	41		
I. ASSETS Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others		58.90 - - - -	41		
Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others (vi) Long term loans and advances (vii) Deferred Tax Asset (Net) (viii) Other non current assets		58.90 - - - -	41		
Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others (vi) Long term loans and advances (vii) Deferred Tax Asset (Net) (viii) Other non current assets		58.90 - - - -	41		
Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others (vi) Long term loans and advances (vii) Deferred Tax Asset (Net) (viii) Other non current assets		58.90 - - - - -	48		
Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others (vi) Long term loans and advances (vii) Deferred Tax Asset (Net) (viii) Other non current assets (a) Inventories (b) Financial assets (b) Financial assets		58.90 - - - -	48		
Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others (vi) Long term loans and advances (vii) Deferred Tax Asset (Net) (viii) Other non current assets		58.90 - - - - -	48		
Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others (vi) Long term loans and advances (vii) Deferred Tax Asset (Net) (viii) Other non current assets 2. Current assets (a) Inventories (b) Financial assets (i) Investments (ii) loans		58.90 - - - - - -	48		
Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others (vi) Long term loans and advances (vii) Deferred Tax Asset (Net) (viii) Other non current assets (a) Inventories (b) Financial assets (i) Investments (ii) Ioans (iii) Short Term Loans & Advances		58.90	48		
Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others (vi) Long term loans and advances (vii) Deferred Tax Asset (Net) (viii) Other non current assets (a) Inventories (b) Financial assets (i) Investments (ii) Ioans (iii) Short Term Loans & Advances (iv) Bank balances		58.90	199 14:		
Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others (vi) Long term loans and advances (vii) Deferred Tax Asset (Net) (viii) Other non current assets (a) Inventories (b) Financial assets (i) Investments (ii) Ioans (iii) Short Term Loans & Advances (vy) Trade Recivables		58.90	199 14: 52:		
I. ASSETS Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others (vi) Long term loans and advances (vii) Deferred Tax Asset (Net) (viii) Other non current assets 2. Current assets (a) Inventories (b) Financial assets (i) Investments (ii) Ioans (iii) Short Term Loans & Advances (iv) Bank balances		58.90	199 141 523		
I. ASSETS I. Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others (vi) Long term loans and advances (vii) Deferred Tax Asset (Net) (viii) Other non current assets 2. Current assets (a) Inventories (b) Financial assets (i) Investments (ii) Ioans (iii) Short Term Loans & Advances (iv) Bank balances (v) Trade Recivables (vi) Cash & Cash Equivalents (f) Other current assets		58.90	199 141 523 5		
I. ASSETS I. Non-current assets (i) Tangible Assets (ii) Intangible assets (iii) Capital work in progress (iv) Intagible assets under development (v) Financial assets (a) Investments (b) Others (vi) Long term loans and advances (vii) Deferred Tax Asset (Net) (viii) Other non current assets 2. Current assets (a) Inventories (b) Financial assets (i) Investments (ii) Ioans (iii) Short Term Loans & Advances (iv) Bank balances (v) Trade Recivables (vi) Cash & Cash Equivalents		58.90	1,018 48 48 199 141 523 5 100 1,018		

As per my report of the even date for Amrutesh Durga & Co.,

Chartered Accountants

for and on behalf of the Board of directors for Confide Pharmaceuticals Private Limited

CA. Amrutesh Durga

Partner Membership No: 219424 F.R.N.: 013370S

UDIN : Place: Bangalore Date: 17-10-2022 Ajay Kumar Mishra Director DIN: 07799251 Kalpana Tripathi Director DIN:07799501

No. 196, 1st Floor Raghavendra Layout, Chikabanavara Bangalore Bangalore KA 560090 CIN: U74999KA2017PTC102597

		CIN: C	J74999KA2017PTC102597						
	PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED MARCH 31, 2022 ₹ In Thousands								
	Particualrs Note No.	As at	As at						
Ţ	INCOME	March 31, 2022	31-Mar-21						
I.	Revenue from Operations	5,019.26	709.84						
	Other Income	29.05	705.0						
		2,100							
II.	TOTAL REVENUE (I + II)	5,048.31	709.84						
III.	EXPENSES	1 200 27	FAC 00						
	Cost of Material Consumed	1,288.36	546.89						
	Employee benefit expense	1,192.40	660.00						
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-							
	Purchase of Stock in Trade								
	Administration & Other expenses	2.49							
	Finance costs	1.89	1.59						
	Depreciation	27.12	32.65						
	Other Expenses	1,721.18	273.48						
	TOTAL EXPENSES	4,233.43	1,514.62						
v	PROFIT BEFORE EXCEPTIONAL AND EXTRAORDINARY ITEMS AND TAX (III-IV)	814.88	-804.79						
	, ,	014.00	-004.7						
	Exceptional items	-	-						
VII.	PROFIT BEFORE EXTRAORDINARY ITEMS AND TAX (V - VI)	814.88	-804.79						
VIII	Extraordinary Items	-	-						
IX.	PROFIT BEFORE TAX (VII- VIII)	814.88	-804.79						
x.	TAX EXPENSE:								
	(1) Current tax								
	(2) Deferred tax		-4.79						
XI.	PROFIT (LOSS) FOR THE PERIOD FROM CONTINUING OPERATIONS (IX - X)	814.88	-800.00						
XII.	Profit/(loss) from discontinuing operations	-	-						
XIII.	Tax expense of discontinuing operations	-	-						
XIV	PROFIT/(LOSS) FROM DISCONTINUING OPERATIONS (AFTER TAX) (XII-XIII)	_	_						
	PROFIT (LOSS) FOR THE PERIOD (XI + XIV)	814.88	-800.00						
	Earnings per equity share:	014.00	-800.00						
	(1) Basic	81.49	-80.00						
	(2) Diluted	81.49	-80.00						
	NOTES FORMING PART OF THE FINANCIAL STATEMENTS 13								
	As per my report of the even date for Amrutesh Durga & Co., Chartered Accountants CA. Amrutesh Durga Partner	for and on behalf of the Board of of Confide Pharmacon Conf	directors euticals Private Limited Kalpana Tripathi Director						

F.R.N.: 013370S UDIN: Place: Bangalore Date: 17-10-2022

No. 196, 1st Floor Raghavendra Layout, Chikabanavara Bangalore Bangalore KA 560090

NOTE FORMING PART OF ACCOUNTS

1. SHARE CAPITAL

The authorised, issued, subscribed and fully paid up share capital comprises of equity shares having par value of INR 10 each as follows:

		₹Ir	Thousands
		As at March 31, 2022	As at March 31, 2021
Authrori	sed	Wiaich 31, 2022	Wiaich 31, 2021
i)	Share Capital	100	100
	Equity Share Capital		
	Authorised Share Capital	100	100
	(10000 shares of `100 each)		
ii)	Issued, Subscribed & fully paid Share capital (1000 shares of `100 each)	100	100
	,	100	100

c) Details of shares held by shareholders holding more than 5% of the aggregate shares in the Company

	As at March 31, 2021 No. of shares Holding in %				
Equity Shares					
Ajay Kumar Mishra	4	40.0%			
Kalpana Tripathi	6	60.0%			
	10	100%			

d) SHARES HELD BY PROMOTORS

Current Reporting Period					
Promotor's Name	% Change during the year				
Ajay Kumar Mishra	0				
Kalpana Tripathi	0				
	0				

2. RESERVES AND SURPLUS

Reserves and surplus consist of the following reserves:

	Particulars	As at	As at
	1 atticulats	March 31, 2022	31-Mar-2021
a)	Securities premium account		
	Opening balance	-650.48	149.51
	Add:- Transferred Surplus in Profit and Loss	814.88	-800.00
	Closing balance	-	-
		164.40	-650.48
b)	Surplus / (Deficit) in Statement of Profit and Loss		
	Opening balance		
	(+) Net Profit/(Net Loss) For the current year	814.88	<i>-7</i> 57.70
	Amount Available For Appropriation	814.88	-757.70
	(-) Loss Appropriation		
	Transferred from General Reserve	814.88	<i>-</i> 757.70
	Net Surplus	-	-
	Total Reserves & Surplus	164.40	-650.48

NOTE FORMING PART C	F ACCOUNTS	
LONG TERM BORROWINGS		
ZONO TZAMI BORROVILVOS		
	As at	As at
	March 31, 2022	31-Mar-2021
UNSECURED LOANS	T	
Loans and advances from related parties	1 025 07	
Loans and advances from related parties	1,025.07 1,025.07	
	1,025.07	
SHORT TERM BORROWINGS		
	As at	As at
	March 31, 2022	31-Mar-2021
Loans and advances from related parties.		
	-	
TRADE PAYABLES	As at March 31, 2022	As at 31-Mar-2021
	Wiaiti 31, 2022	31-Wai-2021
Due to Micro and small enterprises		
Trade Payable - Due to others		1,042.9
	-	1,042.9
OTHER CURRENT LIABILITIES Other Current Liabilities consist of the following:	As at	As at
	March 31, 2022	31-Mar-2021
Deffered Income		
Others		
	-	
7 SHORT TERM PROVISIONS		
	As at	As at
	March 31, 2022	31-Mar-2021
A. J. C. Devell	= 0.00	4= 4
Audit Fee Payable	50.00 448.80	45.
Expenses Payable Salary Payable	380.00	480.0
Salaty Fayable	878.80	525.0

NOTE FORMING PAR	RT OF ACCOUNTS	
8 NON CURRENT INVESTMENTS		
	As at	As at
	March 31, 2022	31-Mar-2021
Fixed Deposits	-	
	-	
O INVENTORIES		
(At lower of cost and net realisable value)	As at	As at
	March 31, 2022	31-Mar-2021
Finished Goods		
Raw Material (including Packing Material)		
	-	
	-	

NOTE FORMING P	ART OF ACCOUNTS	
10 TRADE RECAIVABLES		
	As at	As at
	March 31, 2022	31-Mar-2021
Trade Receivables	1,130.03	52
	_	_
	1,130.03	523.7
11 CASH AND CASH EQUIVALENTS		
	As at	As at
	March 31, 2022	31-Mar-2021
Cash In hand		
Bank Balance	805.36	141.
	- 905.26	- 147.
	805.36	147.0
2 SHORT TERM LOAN AND ADVANCES		
2 STORT TERM ESTATING THE VINCES	As at	As at
	March 31, 2022	31-Mar-2021
Pantal Dancoit Office Promises	40.00	4
Rental Deposit-Office Premises Clinder, Freight & Security Deposits	35.00	35.
TM, R Producrs	35.00	33. 44.
	-	
Adavance Payment to Suppliers Additional Tax Recoverable C.G.	-	80.
	-	-
Advance Tax	-	-
Rental Deposits	-	-
GST Input Tax - Receivable		-
TDS Receivable A.Y 2022-23		-
	75.00	199.
	75.00	199.
3 OTHER CURRENT ASSETS		
	As at	As at
	March 31, 2022	31-Mar-2021
Share Application Money Received	100.00	10
Fixed Assets Scaps		
Other	-	
	100.00	100.

CONFIDE PHARMACEUTICALS PRIVATE LIMITED No. 196, 1st Floor Raghavendra Layout, Chikabanavara Bangalore Bangalore KA 560090

_	NOTE FORMING	PART OF ACCOUNTS	
4.	REVENUES FROM OPERATIONS		
	Revenues from operations consists of the following :	As at	As at
		March 31, 2022	March 31, 2021
	a) Revenue from Services Provided:	5,019.26 5,019.26	709.84 709.84
	J	5,523.25	
5	Other Income	As at	As at
		March 31, 2022	March 31, 2021
	Other Income Write off Sundry Credtors	29.05	
		29.05	-
5	Cost of materials Consumed		
		As at	As at
		March 31, 2022	March 31, 2021
	Opening stock		
	Add: Purchases		
	Import Domestic Purchase	1,288.36	546.89
	Customs Duty	1,288.30	340.05
	Less: Closing stock		
	Less. Closing stock	1,288.36	546.89
7	Change in Inventories		
		As at March 31, 2022	As at March 31, 2021
		Water 31, 2022	Walch 31, 2021
	Inventories at the end of the year:		
	Finished goods		
	Work-in-progress		
	Inventories at the beginning of the year:		
	Finished goods		
	Work-in-progress	-	-
		•	
3.	EMPLOYEE BENEFIT EXPENSES	As at	As at
		March 31, 2022	March 31, 2021
	Salaries and wages	1,160.00	660.00
	ESI Employees Contribution PF Employer Contribution		
	Staff Welfare	32.40	
	Bonus	1,192.40	660.00
	J	3,23,2,30	
9.	FINANACE COST	As at	As at
		March 31, 2022	March 31, 2021
	Bank Charges	1.89	1.59
	Interest on Unsecured loan Bank Interest	-	
	Bank Interest	-	
		189	1 50
		1.89	1.59
).	ADMINISTRATION & OTHER EXPENSES	6-11i	
	Operation and administration expenses consists of the	As at	As at
		March 31, 2022	March 31, 2021
	(A) DIRECT EXPENSES		
	Consumables Generator Exp.		
	Power & Fuel		
	Customs Clearing Charges Freight Inward		
	Transportation Charges	2.49	
		2.49	-
	Indirect Expenses: Bad Debts Write off	44.00	
	Directors Remuneration	660.00	
	Accounting Charges Audit Fees	80.00	45.00
	Office Rent	72.00	78.00
	Business promotional Expenses Office Expenses	405.00	100.30 44.08
	GST Delay Interest	20.10	11.00
		4.32 4.50	
	GST Late Fee Consultancy		
	Consultancy Continous Medical Education	266.40	
	Consultancy Continous Medical Education Conveyance		6.10
	Consultancy Continous Medical Education	266.40	6.10 273.48

CONFIDE PHARMACEUTICALS PRIVATE LIMITED No. 196, 1st Floor Raghavendra Layout, Chikabanavara Bangalore Bangalore KA 560090

NOTE:15 Property, plant and equipment and intangible assets

	Gross Block								Net Block			
Sl. No	Particulars	Rate	Value at the beginning	Addition during the year	Deductio n during the year	Total Value as on 31-03- 2022	Accumulated Depreciation	Depreciatio n for the year	Derpreciation on additions	Total Depreciation for the year	WDV as on 31.3.2022	WDV as on 31.3.2021
1	Computer	63.16%	24.76	-	-	24.76	9.13	9.87	-	19.00	5.76	15.63
2	Furniture and Fixture	25.89%	32.15	-	-	32.15	18.25	3.60	-	21.85	10.30	13.90
3	Office Equipments	45.07%	23.87	-		23.87	5.29	8.37		13.67	10.21	18.58
4	Mobile	13.91%	-	37.91	-	37.91	-	5.27	-	5.27	32.64	22.81
	Total		80.78	37.91	-	118.69	32.67	27.12	-	59.79	58.90	70.92

No. 196, 1st Floor Raghavendra Layout, Chikabanavara Bangalore Bangalore KA 560090

Annexure - A Schedule of Depreciation as per Income Tax Act, 1961

Block	Asset Class	Name of the Asset	W.D.V	Additions	Additions			W.D.V	
			as on	> 180 days	< 180 days	Total	Depreciation	as on	Rate
			01.04.2021					31.03.2022	(%)
			Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	
A	Tangibale	Computers	9	-	-	9	3.75	6	40%
В	Tangibale	Furnituer & Fixures	43	-	-	43	4.30	39	10%
С	Tangibale	Mobile	-	-	38	38	2.84	35	15%
D	Tangibale	Office Equipment	18	-	-	18	2.72	15	15%
Total			71	-	38	108	14	95	